Repligen (NASDAQ:RGEN) Given New $150.00 Price Target at Canaccord Genuity Group

Repligen (NASDAQ:RGEN - Get Free Report) had its price objective cut by research analysts at Canaccord Genuity Group from $170.00 to $150.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a "hold" rating on the biotechnology company's stock. Canaccord Genuity Group's price objective points to a potential upside of 13.95% from the company's previous close.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, April 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $176.82.

Repligen Stock Up 1.3 %

NASDAQ:RGEN traded up $1.64 during trading hours on Wednesday, reaching $131.64. The company had a trading volume of 678,881 shares, compared to its average volume of 708,183. The business's 50-day simple moving average is $140.37 and its two-hundred day simple moving average is $145.78. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52. The firm has a market cap of $7.39 billion, a price-to-earnings ratio of -258.12, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. On average, equities analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In other Repligen news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Institutional Trading of Repligen

A number of hedge funds have recently bought and sold shares of RGEN. Ballentine Partners LLC boosted its stake in Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc increased its position in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC raised its stake in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after purchasing an additional 89 shares during the period. GAMMA Investing LLC grew its stake in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after buying an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.